TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Epidural attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Plasma concentrations of bevenopran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rett Syndrome Behavior Questionnaire (RSBQ) - Fear/Anxiety Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety, Depression, and Mood Scale (ADAMS) - Social Avoidance Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Epileptiform Abnormalities as Assessed Using Electroencephalogram (EEG) Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants by Suicidality Classification as Assessed Using an Adapted Form of the Columbia Classification Algorithm for Suicide Assessment (C-CASA)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Communication Confidence (CCRSA)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Communication Participation Item Bank (CPIB)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Communication Participation Person Centered Goals
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Freedom from all-cause mortality at 30 days Follow Up
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from all-cause mortality at 12 months Follow Up
Endpoint domain: Mortality/survival
Primary endpoint: R0-Resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 24 hour postoperative morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time spent with SpO2 <90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in Dermal Thickness of Sentinel Plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of psoas hematomas
Endpoint domain: Adverse events/effects
Primary endpoint: accuracy of lung biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of colonoscopy with megachannel
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical feasibility of colonoscopy with megachannel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Apixaban Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rivaroxaban Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary albumin excretion rate change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maturation kinetic of oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Optimal weight-based dose of azathioprine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants Who Developed Viral Resistance to Oseltamivir
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Tissue Rejection or Graft Versus Host Disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: 15% fall in forced expiratory volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Correct classification of SARS-CoV-2 infected and not infected subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Losartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Losartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of Losartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Hydrochlorothiazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Hydrochlorothiazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of Hydrochlorothiazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-report craving
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in number of subjects who initiate smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of minutes to first puff
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body composition / bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Caliber variation of the brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Willebrand factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 8-hour mean CK-MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-hour mean CK-MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of diaphragm movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: organ damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: pre intervention pelvic floor muscle measurement attendance rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: start of intervention rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: concordance rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: post intervention data collection attendance rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: staff necessary
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of DBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sagittal plane knee kinetics and kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychological readiness for sports activities via survey scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in motor patterning via electromyography of quadriceps and hamstring muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT density of large vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of in Label Adherent Subjects
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Work capacity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Participants With Good Complete Remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With TRM
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis efficiency of the AI model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke or death within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Any ischemic stroke or revascularization beyond 30 days through 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Diastolic Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Satisfaction with assistive technology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usability of ArmAssist 2.0
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in 1st peak RMS Knee Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 24h morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of sucks per swallow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral bolus control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: presence of aspiration (silent or non-silent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Maximum Post-exercise FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with Lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy for Differentiating Neoplastic and Non-neoplastic Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity for Differentiating Neoplastic and Non-neoplastic Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity for Differentiating Neoplastic and Non-neoplastic Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: uroflowmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in TSLP Gene Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Best Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Tumor Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: plasma concentrations of interleukins (IL-1 and IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentrations of substance P
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs and symptoms evaluated by a PHYSICIAN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duruöz Hand Index (DHI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Brain Glucose Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With One or More Serious/Other Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clearance of leg telangiectasias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain classification
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anemia Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Thigh circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Identification of fungal species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Median Percent Change in Primary Generalized Tonic Clonic Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: 50% Responder Rate for Primary Generalized Tonic Clonic Seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: 50% Responder Rate in Primary Generalized Tonic-Clonic Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Mean Absolute Change in Hb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Disease activity status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of re-operations of ipsilateral chronic subdural hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Patients' preference for telemedicine vs in-person assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference of pain at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gambling Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: thoracoabdominal kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mobility diaphragmatic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: miRNA expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to Ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in maximal exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose, Urea and Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sodium, Potassium, Chloride and CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Glutamic Pyruvic Transaminase and Serum Glutamic Oxaloacetic Transaminase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: White Blood Cell, Hemoglobin and Platelet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Days of return of bowel function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain score by Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers of Anti-H3 and B Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of favourable and unfavourable opinions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects With AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Insulin Resistance (HOMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: evaluation of radiographic images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Patients Who Mobilize and Collect at Least Half of the Total Target CD34+ Cell Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in percentage of neutrophils in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Glucagon-like Peptide-1 Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of Grade 2-4 Acute Graft Versus Host Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Cervical intraepithelial neoplasia 2+ (CIN2+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patient-rated neck and back disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Groton Maze Learning Test (GMLT) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ASD Symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Level
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Language Level
Endpoint domain: Life impact
Endpoint subdomain: Communication functioning
Primary endpoint: Adaptive Functioning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Amount of needle positioning needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in functional performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported health-related quality of life (HRQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Body Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative tramadol consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of MDRGNB colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Difference in MARIA(R) outputs with M5 and M6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in MARIA(R) outputs when stationary vs moved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dielectric constant of aspirated cyst fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASS_C questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: positive predictive value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: negative predictive value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bone strength parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in ocular symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Discontinuation of Dual Antiplatelet Drug
Endpoint domain: Adverse events/effects
Primary endpoint: MMP-2 and MMP-9/NGAL ratio in tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Stress Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Emotional Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in Nuclear factor kappa-light-chain-enhancer of activated B cells at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in Fructosamine at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Homocysteine at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stool Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Care Path Behavioral Assessment (CPBA), Pre-surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Care Path Behavioral Assessment (CPBA), Post-surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in blood glucose Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of 13C-DHA in red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Trunk Control Measurement Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk Muscle Tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Segmental Assessment of Trunk Control Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance Assessment System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-Minute Walking Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactogenicity of Candidate Malaria Vaccine FMP013/ALFQ
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA <50 c/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of antibiotic prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of Participants Attaining Target Trough of 15-20 mg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (AEs) (All Causalities)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-emergent AEs (Treatment-Related)
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy measured by visual analog scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patients Alive
Endpoint domain: Mortality/survival
Primary endpoint: Extent of peri-incisional hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of chronic pain 6 months after laparotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Numbers of Peptide-specific CD8+ T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse Events Experienced by Subjects
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Average Daily Opioid Dose in Morphine Equivalent Dose (MED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Network Analysis group patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events related to the filtration procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events related to the system catheter insertion
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of ICU delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of sleep apnea syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep